Omaima M. Sabek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Omaima M. Sabek has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
A. Osama Gaber
The Houston Methodist Hospital
18 shared publications- Mostafa Waleed Gaber
Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, United States of America
14 shared publications Daniel W. Fraga
Department of Surgery The Methodist Hospital Houston TX USA
10 shared publications- Janice A. Zawaski
NASA Johnson Space Center , Houston, TX 77058
10 shared publications Malak Kotb
Department of Surgery, Division of Transplantation, University of Tennessee, Memphis, TN, USA
10 shared publicationsJames Henry
Environmental Health and Safety, St. Jude Children's Research Hospital, Memphis, TN, USA
7 shared publications
Latest Publications
- Open Access
- 13 June 2025
- Published by Springer Nature in Research Square
Osteocalcin induces phosphorylation of FOXO1 in human beta-cells and restores insulin expression under hyperglycemic conditions
Forkhead box O1 (FOXO1) is a key transcription factor that plays an important role in pancreatic β-cell compensation under physiological and pathological conditions and serves as a key regulator of glucose homeostasis. While FOXO1 expression in osteoblasts contributes to glucose maintenance through regulating osteocalcin, interestingly, osteocalcin acts directly on β-cells by regulating PDX1 and insulin expression. Here, we investigate the effect of osteocalcin on the FOXO1 expression in human pancreatic β-cells. In a human β-cell line and pancreatic islets, the fate of FOXO1 binding to the PDX1 promoter was investigated after osteocalcin treatment, with or without AKT inhibition. Furthermore, we investigated the effect of osteocalcin on PDX1 and insulin gene expression as well as the subcellular localization of FOXO1 and PDX1 in human islets. The data show that osteocalcin treatment increased the amount of phosphorylated FOXO1-S256 via AKT in human islet from high BMI donor. Moreover, human islets from donors with and without diabetes treated with osteocalcin showed a reduced nuclear FOXO1 and an increase in nuclear PDX1. In a human β-cell line and pancreatic islets, osteocalcin increases insulin and PDX1 expression following phosphorylation-dependent ubiquitination and degradation of FOXO1 via the protein kinase B pathway.
- 13 June 2025
- Published by Springer Nature in Research Square
Open AccessOsteocalcin induces phosphorylation of FOXO1 in human beta-cells and restores insulin expression under hyperglycemic conditions
Forkhead box O1 (FOXO1) is a key transcription factor that plays an important role in pancreatic β-cell compensation under physiological and pathological conditions and serves as a key regulator of glucose homeostasis. While FOXO1 expression in osteoblasts contributes to glucose maintenance through regulating osteocalcin, interestingly, osteocalcin acts directly on β-cells by regulating PDX1 and insulin expression. Here, we investigate the effect of osteocalcin on the FOXO1 expression in human pancreatic β-cells. In a human β-cell line and pancreatic islets, the fate of FOXO1 binding to the PDX1 promoter was investigated after osteocalcin treatment, with or without AKT inhibition. Furthermore, we investigated the effect of osteocalcin on PDX1 and insulin gene expression as well as the subcellular localization of FOXO1 and PDX1 in human islets. The data show that osteocalcin treatment increased the amount of phosphorylated FOXO1-S256 via AKT in human islet from high BMI donor. Moreover, human islets from donors with and without diabetes treated with osteocalcin showed a reduced nuclear FOXO1 and an increase in nuclear PDX1. In a human β-cell line and pancreatic islets, osteocalcin increases insulin and PDX1 expression following phosphorylation-dependent ubiquitination and degradation of FOXO1 via the protein kinase B pathway.
- 2 February 2024
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 100 (4) , 565-572
High variability in short and long-term recovery kinetic of blood cell count and blood chemistry in a partial body irradiation mouse model
PurposeIn the aftermath of a nuclear disaster or accident, survivors will suffer from radiation-induced normal tissue damage. Recovery after radiation exposure is dictated by several factors, one of which is degree of shielding at time of exposure. This study aims to characterize the short and late term changes in kinetics and magnitude of pancytopenia and blood chemistry in a model of heterogeneous radiation exposure, or partial body irradiation (PBI), compared to whole body irradiation (WBI).Materials and methodsMale C57BL/6 mice, 8-10 weeks of age, were WBI at 6 different doses (6, 6.1. 6.15, 6.2, 6.5, and 7.5 Gy) to establish the LD50. To determine the effect of shielding on blood cell counts and chemistry, animals were either WBI at 6 Gy (LD2230) or 6 Gy PBI with one leg shielding (LD030). Complete blood counts and chemistry were measured at 1, 5-, 10-, 20-, 30- and 120-days post-irradiation.Results and conclusionsIrradiated animals had significant depletion of white blood cells, red blood cells and platelets up to 10 days post-irradiation. Separation between PBI and WBI were observed at 10- and 20-days post-irradiation at which point PBI animals showed sign of recovery while overall cell count remains depleted in WBI animals up to 30 days post-irradiation. In addition, significant changes were found in parameters indicative of hematopoietic injury including hemoglobin count, hematocrit count and white blood cell population. Significant changes were observed in kidney function with changes to blood urea nitrogen and calcium concentration at 5-days post-irradiation. At 10-days post-irradiation. liver function changes differentiated WBI from PBI animals. Long-term, irradiated animal's chemistry values and many blood counts were not significantly different from Sham. In conclusion, partial shielding ensured complete survival and demonstrated a different recovery kinetics of blood and chemistry parameters after irradiation compared to survivors of whole body irradiation and no single hemopoietic parameter was able to consistently differentiate irradiated from Sham animals. This seems to indicate that there is no single robust hemopoietic parameter to differentiate those exposed from those who were not due to the inherent variability in individual responses. Furthermore, there were no significant long-term effects on these blood parameters between survivors of WBI and PBI except that shielding accelerated recovery.
- 2 February 2024
- Published by Taylor & Francis in International Journal of Radiation Biology
- Vol. 100 (4) , 565-572
High variability in short and long-term recovery kinetic of blood cell count and blood chemistry in a partial body irradiation mouse model
PurposeIn the aftermath of a nuclear disaster or accident, survivors will suffer from radiation-induced normal tissue damage. Recovery after radiation exposure is dictated by several factors, one of which is degree of shielding at time of exposure. This study aims to characterize the short and late term changes in kinetics and magnitude of pancytopenia and blood chemistry in a model of heterogeneous radiation exposure, or partial body irradiation (PBI), compared to whole body irradiation (WBI).Materials and methodsMale C57BL/6 mice, 8-10 weeks of age, were WBI at 6 different doses (6, 6.1. 6.15, 6.2, 6.5, and 7.5 Gy) to establish the LD50. To determine the effect of shielding on blood cell counts and chemistry, animals were either WBI at 6 Gy (LD2230) or 6 Gy PBI with one leg shielding (LD030). Complete blood counts and chemistry were measured at 1, 5-, 10-, 20-, 30- and 120-days post-irradiation.Results and conclusionsIrradiated animals had significant depletion of white blood cells, red blood cells and platelets up to 10 days post-irradiation. Separation between PBI and WBI were observed at 10- and 20-days post-irradiation at which point PBI animals showed sign of recovery while overall cell count remains depleted in WBI animals up to 30 days post-irradiation. In addition, significant changes were found in parameters indicative of hematopoietic injury including hemoglobin count, hematocrit count and white blood cell population. Significant changes were observed in kidney function with changes to blood urea nitrogen and calcium concentration at 5-days post-irradiation. At 10-days post-irradiation. liver function changes differentiated WBI from PBI animals. Long-term, irradiated animal's chemistry values and many blood counts were not significantly different from Sham. In conclusion, partial shielding ensured complete survival and demonstrated a different recovery kinetics of blood and chemistry parameters after irradiation compared to survivors of whole body irradiation and no single hemopoietic parameter was able to consistently differentiate irradiated from Sham animals. This seems to indicate that there is no single robust hemopoietic parameter to differentiate those exposed from those who were not due to the inherent variability in individual responses. Furthermore, there were no significant long-term effects on these blood parameters between survivors of WBI and PBI except that shielding accelerated recovery.
- 2 February 2024
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 261 (1)
Osteocalcin protects islet identity in low-density lipoprotein receptor knockout mice on high-fat diet
Metabolic syndrome (MetS) is an increasing global health threat and strong risk factor for type 2 diabetes (T2D). MetS causes both hyperinsulinemia and islet size overexpansion, and pancreatic β-cell failure impacts insulin and proinsulin secretion, mitochondrial density, and cellular identity loss. The low-density lipoprotein receptor knockout (LDLr−/−) model combined with high-fat diet (HFD) has been used to study alterations in multiple organs, but little is known about the changes to β-cell identity resulting from MetS. Osteocalcin (OC), an insulin-sensitizing protein secreted by bone, shows promising impact on β-cell identity and function. LDLr−/− mice at 12 months were fed chow or HFD for 3 months ± 4.5 ng/h OC. Islets were examined by immunofluorescence for alterations in nuclear Nkx6.1 and PDX1 presence, insulin–glucagon colocalization, islet size and %β-cell and islet area by insulin and synaptophysin, and mitochondria fluorescence intensity by Tomm20. Bone mineral density (BMD) and %fat changes were examined by Piximus Dexa scanning. HFD-fed mice showed fasting hyperglycemia by 15 months, increased weight gain, %fat, and fasting serum insulin and proinsulin; concurrent OC treatment mitigated weight increase and showed lower proinsulin-to-insulin ratio, and higher BMD. HFD increased %β and %islet area, while simultaneous OC-treatment with HFD was comparable to chow-fed mice. Significant reductions in nuclear PDX1 and Nkx6.1 expression, increased insulin–glucagon colocalization, and reduction in β-cell mitochondria fluorescence intensity were noted with HFD, but largely prevented with OC administration. OC supplementation here suggests a benefit to β-cell identity in LDLr−/− mice and offers intriguing clinical implications for countering metabolic syndrome.
- 2 February 2024
- Published by Bioscientifica in Journal of Endocrinology
- Vol. 261 (1)
Osteocalcin protects islet identity in low-density lipoprotein receptor knockout mice on high-fat diet
Metabolic syndrome (MetS) is an increasing global health threat and strong risk factor for type 2 diabetes (T2D). MetS causes both hyperinsulinemia and islet size overexpansion, and pancreatic β-cell failure impacts insulin and proinsulin secretion, mitochondrial density, and cellular identity loss. The low-density lipoprotein receptor knockout (LDLr−/−) model combined with high-fat diet (HFD) has been used to study alterations in multiple organs, but little is known about the changes to β-cell identity resulting from MetS. Osteocalcin (OC), an insulin-sensitizing protein secreted by bone, shows promising impact on β-cell identity and function. LDLr−/− mice at 12 months were fed chow or HFD for 3 months ± 4.5 ng/h OC. Islets were examined by immunofluorescence for alterations in nuclear Nkx6.1 and PDX1 presence, insulin–glucagon colocalization, islet size and %β-cell and islet area by insulin and synaptophysin, and mitochondria fluorescence intensity by Tomm20. Bone mineral density (BMD) and %fat changes were examined by Piximus Dexa scanning. HFD-fed mice showed fasting hyperglycemia by 15 months, increased weight gain, %fat, and fasting serum insulin and proinsulin; concurrent OC treatment mitigated weight increase and showed lower proinsulin-to-insulin ratio, and higher BMD. HFD increased %β and %islet area, while simultaneous OC-treatment with HFD was comparable to chow-fed mice. Significant reductions in nuclear PDX1 and Nkx6.1 expression, increased insulin–glucagon colocalization, and reduction in β-cell mitochondria fluorescence intensity were noted with HFD, but largely prevented with OC administration. OC supplementation here suggests a benefit to β-cell identity in LDLr−/− mice and offers intriguing clinical implications for countering metabolic syndrome.
- Open Access
- 16 September 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (10) , e1367
Pretransplant HOMA-β Is Predictive of Insulin Independence in 7 Patients With Chronic Pancreatitis Undergoing Islet Autotransplantation
Background.: Islet and β-cell function is intrinsic to glucose homeostasis. Pancreatectomy and islet autotransplantation (PIAT) for chronic pancreatitis (CP) treatment is a useful model for assessing islet function in the absence of immune-suppression and to perform extensive presurgical metabolic evaluations not possible from deceased donors. We recently showed that in CP-PIAT patients, preoperative islet identity loss presented with postoperative glycemic loss. Here, we examine presurgical islet function using Homeostatic Model Assessment-Beta Cell Function (%) (HOMA-β) and glycemic variables and compared them with postsurgical insulin independence and their predicted alignment with Secretory Unit of Islet Transplant Objects (SUITO) and beta cell score after transplantation (BETA-2) scores. Methods.: Seven CP-PIAT patients were assessed for β-cell function metrics, including pretransplant and 6-mo posttransplant HOMA-β using insulin and C-peptide and evaluations of proposed insulin independence by SUITO and BETA-2 graft function equations. These were compared with oral glucose tolerance tests and pancreas histological samples taken at the time of transplant, examined for β-cell maturity markers. Results.: Pre-PIAT, HOMA-β (60%−100%) associated with post-PIAT insulin independence. This association was only moderately supported by post-PIAT SUITO threshold scores (≥26) but robustly by BETA-2 scores (≥16.2). Appropriate posttransplant oral glucose tolerance test curves were found in those patients with normal pretransplant HOMA-β values. Preoperative low serological β-cell function was displayed by concurrent evidence of β-cell identity alterations including colocalization of insulin and glucagon, loss of urocortin-3, and increased intra-islet vimentin in patients who were insulin-dependent post-PIAT. Conclusions.: These data encourage HOMA-β assessment before PIAT for estimating posttransplant insulin independence.
- 16 September 2022
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 8 (10) , e1367
Open AccessPretransplant HOMA-β Is Predictive of Insulin Independence in 7 Patients With Chronic Pancreatitis Undergoing Islet Autotransplantation
Background.: Islet and β-cell function is intrinsic to glucose homeostasis. Pancreatectomy and islet autotransplantation (PIAT) for chronic pancreatitis (CP) treatment is a useful model for assessing islet function in the absence of immune-suppression and to perform extensive presurgical metabolic evaluations not possible from deceased donors. We recently showed that in CP-PIAT patients, preoperative islet identity loss presented with postoperative glycemic loss. Here, we examine presurgical islet function using Homeostatic Model Assessment-Beta Cell Function (%) (HOMA-β) and glycemic variables and compared them with postsurgical insulin independence and their predicted alignment with Secretory Unit of Islet Transplant Objects (SUITO) and beta cell score after transplantation (BETA-2) scores. Methods.: Seven CP-PIAT patients were assessed for β-cell function metrics, including pretransplant and 6-mo posttransplant HOMA-β using insulin and C-peptide and evaluations of proposed insulin independence by SUITO and BETA-2 graft function equations. These were compared with oral glucose tolerance tests and pancreas histological samples taken at the time of transplant, examined for β-cell maturity markers. Results.: Pre-PIAT, HOMA-β (60%−100%) associated with post-PIAT insulin independence. This association was only moderately supported by post-PIAT SUITO threshold scores (≥26) but robustly by BETA-2 scores (≥16.2). Appropriate posttransplant oral glucose tolerance test curves were found in those patients with normal pretransplant HOMA-β values. Preoperative low serological β-cell function was displayed by concurrent evidence of β-cell identity alterations including colocalization of insulin and glucagon, loss of urocortin-3, and increased intra-islet vimentin in patients who were insulin-dependent post-PIAT. Conclusions.: These data encourage HOMA-β assessment before PIAT for estimating posttransplant insulin independence.
- Open Access
- 12 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Human pancreatic microenvironment promotes β-cell differentiation via non-canonical WNT5A/JNK and BMP signaling
In vitro derivation of pancreatic β-cells from human pluripotent stem cells holds promise as diabetes treatment. Despite recent progress, efforts to generate physiologically competent β-cells are still hindered by incomplete understanding of the microenvironment’s role in β-cell development and maturation. Here, we analyze the human mesenchymal and endothelial primary cells from weeks 9-20 fetal pancreas and identify a time point-specific microenvironment that permits β-cell differentiation. Further, we uncover unique factors that guide in vitro development of endocrine progenitors, with WNT5A markedly improving human β-cell differentiation. WNT5A initially acts through the non-canonical (JNK/c-JUN) WNT signaling and cooperates with Gremlin1 to inhibit the BMP pathway during β-cell maturation. Interestingly, we also identify the endothelial-derived Endocan as a SST+ cell promoting factor. Overall, our study shows that the pancreatic microenvironment-derived factors can mimic in vivo conditions in an in vitro system to generate bona fide β-cells for translational applications.
- 12 April 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-18
Open AccessHuman pancreatic microenvironment promotes β-cell differentiation via non-canonical WNT5A/JNK and BMP signaling
In vitro derivation of pancreatic β-cells from human pluripotent stem cells holds promise as diabetes treatment. Despite recent progress, efforts to generate physiologically competent β-cells are still hindered by incomplete understanding of the microenvironment’s role in β-cell development and maturation. Here, we analyze the human mesenchymal and endothelial primary cells from weeks 9-20 fetal pancreas and identify a time point-specific microenvironment that permits β-cell differentiation. Further, we uncover unique factors that guide in vitro development of endocrine progenitors, with WNT5A markedly improving human β-cell differentiation. WNT5A initially acts through the non-canonical (JNK/c-JUN) WNT signaling and cooperates with Gremlin1 to inhibit the BMP pathway during β-cell maturation. Interestingly, we also identify the endothelial-derived Endocan as a SST+ cell promoting factor. Overall, our study shows that the pancreatic microenvironment-derived factors can mimic in vivo conditions in an in vitro system to generate bona fide β-cells for translational applications.
- Open Access
- 1 April 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (5) , 1508-1520
NF-κB Blockade by NEMO Binding Domain Peptide Ameliorates Inflammation and Neurobehavioral Sequelae After Cranial Radiation Therapy in Juvenile Mice
- 1 April 2021
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 109 (5) , 1508-1520
Open AccessNF-κB Blockade by NEMO Binding Domain Peptide Ameliorates Inflammation and Neurobehavioral Sequelae After Cranial Radiation Therapy in Juvenile Mice
- Open Access
Tead1 reciprocally regulates adult β-cell proliferation and function to maintain glucose homeostasis
Summary: Proliferative quiescence in β-cells is required to maintain functional competence. While this presents a significant hurdle in regenerative therapy for diabetes, the molecular underpinnings of this reciprocal relationship remain unclear. Here, we demonstrate that TEAD1, the transcription effector of the mammalian-Hippo pathway, drives developmental stage-specific β-cell proliferative capacity in conjunction with its functional maturation. TEAD1 promotes adult β-cell mature identity by direct transcriptional control of a network of critical β-cell transcription factors, including, Pdx1, Nkx6.1, and MafA, while its regulation of Cdkn2a maintains proliferative quiescence. Consequently, mice with either constitutive or inducible genetic deletion of TEAD1 in β-cells developed overt diabetes due to a severe loss of secretory function despite induction of proliferation. Furthermore, we show that TEAD1 has a similar regulatory role in human β-cells. Consistent with this function in β-cells, variants in TEAD1 have been associated with c-HOMA-B in American Indians. We propose that TEAD1 is an essential intrinsic molecular switch coordinating adult β-cell proliferative quiescence with mature identity and its differential modulation may be necessary to overcome the challenge of inducing proliferation with functional competence in human beta cells.
Open AccessTead1 reciprocally regulates adult β-cell proliferation and function to maintain glucose homeostasis
Summary: Proliferative quiescence in β-cells is required to maintain functional competence. While this presents a significant hurdle in regenerative therapy for diabetes, the molecular underpinnings of this reciprocal relationship remain unclear. Here, we demonstrate that TEAD1, the transcription effector of the mammalian-Hippo pathway, drives developmental stage-specific β-cell proliferative capacity in conjunction with its functional maturation. TEAD1 promotes adult β-cell mature identity by direct transcriptional control of a network of critical β-cell transcription factors, including, Pdx1, Nkx6.1, and MafA, while its regulation of Cdkn2a maintains proliferative quiescence. Consequently, mice with either constitutive or inducible genetic deletion of TEAD1 in β-cells developed overt diabetes due to a severe loss of secretory function despite induction of proliferation. Furthermore, we show that TEAD1 has a similar regulatory role in human β-cells. Consistent with this function in β-cells, variants in TEAD1 have been associated with c-HOMA-B in American Indians. We propose that TEAD1 is an essential intrinsic molecular switch coordinating adult β-cell proliferative quiescence with mature identity and its differential modulation may be necessary to overcome the challenge of inducing proliferation with functional competence in human beta cells.
- Open Access
- 29 November 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 3 (1) , e00104
Serum C‐peptide and osteocalcin levels in children with recently diagnosed diabetes
Background: We explored the association of C‐peptide (marker of secreted insulin), proinsulin and proinsulin ⁄C‐peptide ratio (PI/C) (markers of beta‐cell endoplasmic reticulum [ER] stress) with undercarboxylated (uOC) and carboxylated osteocalcin (cOC) and their ratio (uOC/cOC) in children with recently diagnosed type 1 (T1D) or type 2 diabetes (T2D), and the correlation of these variables with partial remission (PR) in children with T1D.Methods: Demographic and clinical data of children with new‐onset diabetes (n = 68; median age = 12.2 years; 33.8% non‐Hispanic White, 45.6% Hispanic/Latino, 16.2% African American and 4.4% other) were collected at diagnosis and during the first (V1), second (V2) and third clinical visits at 9.0, 32.0 and 175.7 weeks, respectively. Serum proinsulin, C‐peptide, uOC and cOC values were measured 7.0 weeks after diagnosis. PR was defined as insulin dose–adjusted HbA1c (IDAA1c) ≤9.Results: In children with new‐onset T1D with DKA (33.3%) or T2D (29.4%), Spearman's correlation coefficient revealed a positive association between the C‐peptide levels and both uOC and uOC/cOC ratio. In T1D (n = 48), both higher serum C‐peptide levels and low PI:C ratio were associated with higher BMI percentile (β = 0.02, P = .001; β = −0.01, P = .02, respectively) and older age at diagnosis (β = 0.13, P = .001; β = −0.12, P = .001, respectively). Furthermore, in children with T1D, C‐peptide levels at V1 correlated with IDAA1c ≤ 9 at V1 (P = .04).Conclusion: C‐peptide levels are associated with a higher uOC and uOC/cOC ratio in paediatric diabetes. In new‐onset T1D children, older age and higher BMI were associated with lower beta‐cell stress and higher preserved function, which was predictive of PR on follow‐up.
- 29 November 2019
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 3 (1) , e00104
Open AccessSerum C‐peptide and osteocalcin levels in children with recently diagnosed diabetes
Background: We explored the association of C‐peptide (marker of secreted insulin), proinsulin and proinsulin ⁄C‐peptide ratio (PI/C) (markers of beta‐cell endoplasmic reticulum [ER] stress) with undercarboxylated (uOC) and carboxylated osteocalcin (cOC) and their ratio (uOC/cOC) in children with recently diagnosed type 1 (T1D) or type 2 diabetes (T2D), and the correlation of these variables with partial remission (PR) in children with T1D.Methods: Demographic and clinical data of children with new‐onset diabetes (n = 68; median age = 12.2 years; 33.8% non‐Hispanic White, 45.6% Hispanic/Latino, 16.2% African American and 4.4% other) were collected at diagnosis and during the first (V1), second (V2) and third clinical visits at 9.0, 32.0 and 175.7 weeks, respectively. Serum proinsulin, C‐peptide, uOC and cOC values were measured 7.0 weeks after diagnosis. PR was defined as insulin dose–adjusted HbA1c (IDAA1c) ≤9.Results: In children with new‐onset T1D with DKA (33.3%) or T2D (29.4%), Spearman's correlation coefficient revealed a positive association between the C‐peptide levels and both uOC and uOC/cOC ratio. In T1D (n = 48), both higher serum C‐peptide levels and low PI:C ratio were associated with higher BMI percentile (β = 0.02, P = .001; β = −0.01, P = .02, respectively) and older age at diagnosis (β = 0.13, P = .001; β = −0.12, P = .001, respectively). Furthermore, in children with T1D, C‐peptide levels at V1 correlated with IDAA1c ≤ 9 at V1 (P = .04).Conclusion: C‐peptide levels are associated with a higher uOC and uOC/cOC ratio in paediatric diabetes. In new‐onset T1D children, older age and higher BMI were associated with lower beta‐cell stress and higher preserved function, which was predictive of PR on follow‐up.
- Open Access
Cross-sectional evaluation of the relationship between vitamin D status and supplement use across levels of kidney function in adults
Objectives: The objective of this study was to assess vitamin D status of US non-pregnant adults using a standardised assay across 15 mL/min/1.73 m 2 increments of kidney function, report the use of dietary supplements containing vitamin D and assess relationships between vitamin D and markers of bone resorption. Design: This study is a cross-sectional evaluation. Setting: The study is from the US National Health and Nutrition Evaluation Survey in 2001–2012. Participants: The participants were non-institutionalised, non-pregnant adults, age ≥20 years. Primary and secondary outcome measures: The primary outcome measure was serum 25OHD evaluated using liquid chromatography-tandem mass spectroscopy traceable to international reference standards. Secondary outcome measures were use of dietary supplements containing vitamin D and the serum intact parathyroid hormone and bone-specific alkaline phosphatase in a subset of participants. Results: The median 25OHD concentration in 27 543 US non-pregnant adults was 25.7 ng/mL (range, 2.2–150.0 ng/mL). Vitamin D supplements were used by 38.0%; mean (SE)=757 (43) international units/day. The range of 25OHD concentration across groups, stratified by kidney function, was 23.0–28.1 ng/mL. The lowest concentration of 25OHD observed was in people with higher kidney function (23.0 ng/mL for estimated glomerular filtration rate >105 mL/min/1.73 m 2 ). Only 24% of people not taking a dietary supplement had a 25OHD concentration >30 ng/mL. Serum intact parathyroid hormone inversely correlated with 25OHD within all kidney function groups. Bone-specific alkaline phosphatase was also negatively associated with 25OHD concentration. Conclusions: These data indicate that 25OHD concentrations and supplement use may be suboptimal in a significant proportion of the population, across all kidney function levels. The response of bone resorption markers further suggests that 25OHD levels could be improved. Together, these data support a re-evaluation of the 25OHD concentration associated with health in adults.
Open AccessCross-sectional evaluation of the relationship between vitamin D status and supplement use across levels of kidney function in adults
Objectives: The objective of this study was to assess vitamin D status of US non-pregnant adults using a standardised assay across 15 mL/min/1.73 m 2 increments of kidney function, report the use of dietary supplements containing vitamin D and assess relationships between vitamin D and markers of bone resorption. Design: This study is a cross-sectional evaluation. Setting: The study is from the US National Health and Nutrition Evaluation Survey in 2001–2012. Participants: The participants were non-institutionalised, non-pregnant adults, age ≥20 years. Primary and secondary outcome measures: The primary outcome measure was serum 25OHD evaluated using liquid chromatography-tandem mass spectroscopy traceable to international reference standards. Secondary outcome measures were use of dietary supplements containing vitamin D and the serum intact parathyroid hormone and bone-specific alkaline phosphatase in a subset of participants. Results: The median 25OHD concentration in 27 543 US non-pregnant adults was 25.7 ng/mL (range, 2.2–150.0 ng/mL). Vitamin D supplements were used by 38.0%; mean (SE)=757 (43) international units/day. The range of 25OHD concentration across groups, stratified by kidney function, was 23.0–28.1 ng/mL. The lowest concentration of 25OHD observed was in people with higher kidney function (23.0 ng/mL for estimated glomerular filtration rate >105 mL/min/1.73 m 2 ). Only 24% of people not taking a dietary supplement had a 25OHD concentration >30 ng/mL. Serum intact parathyroid hormone inversely correlated with 25OHD within all kidney function groups. Bone-specific alkaline phosphatase was also negatively associated with 25OHD concentration. Conclusions: These data indicate that 25OHD concentrations and supplement use may be suboptimal in a significant proportion of the population, across all kidney function levels. The response of bone resorption markers further suggests that 25OHD levels could be improved. Together, these data support a re-evaluation of the 25OHD concentration associated with health in adults.
- Open Access
- 29 October 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1568-1576
Variability in endocrine cell identity in patients with chronic pancreatitis undergoing islet autotransplantation
- 29 October 2018
- Published by Elsevier in American Journal of Transplantation
- Vol. 19 (5) , 1568-1576
Open AccessVariability in endocrine cell identity in patients with chronic pancreatitis undergoing islet autotransplantation